多形膠芽細胞腫治療(GBM)の世界市場

Transparency Market Researchが発行した調査報告書(TMR602203)
◆英語タイトル:Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
◆商品コード:TMR602203
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2015年6月
◆ページ数:101
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD4,795 ⇒換算¥517,860見積依頼/購入/質問フォーム
Multi UserUSD7,795 ⇒換算¥841,860見積依頼/購入/質問フォーム
Corporate LicenseUSD10,795 ⇒換算¥1,165,860見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、多形膠芽細胞腫治療 (GBM) の世界市場について調査・分析し、多形膠芽細胞腫治療 (GBM) の世界市場概要、市場動向、市場規模、主要地域別分析、関連企業情報などをお届けいたします。
【レポートの概要】

Glioblastoma multiforme (GBM) is the most frequent and lethal primary brain tumor in adults. The current treatment modalities available in the market are surgical resection followed by chemotherapy and radiotherapy, that unable to increase the overall survival of patient. The main reason behind inability of these treatments are frequent recurrence, invasiveness of GBM and resistance of glioma stem cells to conventional treatments. Therefore, novel alternative treatment strategies are desperately needed and pipeline of GBM already involves a mix of biological, immunotherapy, small molecules and other types of therapeutics. Recent advancements in molecular biology and gene technology have provided attractive novel treatment possibilities for the patients diagnosed with GBM.

This research report on the glioblastoma treatment market explains various advancements in this market and analyzes the global glioblastoma treatment market based on drugs (commercially available and pipeline) and geographic regions. The report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments dominating the market and expected to grow at the highest growth rate during the forecast period are included in the report in a precise manner.

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global glioblastoma treatment market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis and Porter’s Five Forces analysis and key players’ market share analysis in 2013 in the glioblastoma treatment market. The research report also provides event impact analysis and various drug delivery methods such as nucleic acid delivery method and biomedical delivery method for the treatment of glioblastoma.

Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. The report on glioblastoma market also provides % compound annual growth rate (CAGR) for each of the market segments mentioned above for the forecast period from 2014 to 2022, considering 2013 as the base year.

【レポートの目次】

Chapter 1 Preface
1.1 Report Description

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022)
2.2 Global Glioblastoma Multiforme Treatment Market, by Drug, 2013 (USD Million)
2.3 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2013 and 2022 (Value %)

Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Disease Overview
3.2.1 Subtypes of Glioblastoma Multiforme
3.2.1.1 Signatures and Clinical features of GBM subtypes
3.2.2 Epidemiology
3.2.3 Standard treatment options and alternative therapeutics approaches
3.3 Nucleic Acid Delivery Methods
3.3.1 Virus-based
3.3.2 Nonviral-based
3.3.3 Stem cells
3.4 In Vivo Identification of GBM for Diagnostic Implication
3.4.1 Magnetic Resonance Imaging (MRI)
3.4.2 Computed Tomography (CT)
3.4.3 Positron Emission Tomography (PET)
3.4.4 Others
3.5 Biomolecule delivery systems
3.5.1 For Glioblastoma
3.5.1.1 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma
3.5.2 For other Central Nervous System (CNS) disorders
3.6 Market Dynamics
3.6.1 Drivers
3.6.1.1 Rising geriatric population will drive the GBM treatment market as they are more prone to cause GBM
3.6.1.2 Global Rate of Aging Population
3.6.1.3 Various government and non-government organizations are creating worldwide awareness against GBM
3.6.1.4 The future of glioblastoma treatment market expects introduction of several novel therapies due to its strong pipeline
3.6.2 Restraints
3.6.2.1 GBM is highly resistant to DNA modifying agents hence available therapies have limitations
3.6.2.2 The overall survival period delivered by current FDA approved treatments is less
3.6.3 Opportunities
3.6.3.1 Development of immunotherapy and biological therapy treatments along with novel drug delivery systems add advantage over the current conventional treatments
3.7 Event Impact Analysis
3.8 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million)
3.8.1 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million)
3.8.2 Bevacizumab (Avastin)
3.8.2.1 Global Bevacizumab Market Revenue, 2012 – 2022 (USD Million)
3.8.3 Temozolomide
3.8.3.1 Global Temozolomide Market Revenue, 2012 – 2022 (USD Million)
3.8.4 Carmustine (BiCNU)
3.8.4.1 Global Carmustine (BiCNU) Market Revenue, 2012 – 2022 (USD Million)
3.9 Global Glioblastoma Treatment Market Revenue and Forecast, by Geography, 2012 – 2022 (USD Million)
3.9.1 North America
3.9.1.1 North America Glioblastoma Treatment Market Revenue, 2012 – 2022 (USD Million)
3.9.2 Europe
3.9.2.1 Europe Glioblastoma Treatment Market Revenue, 2012 – 2022 (USD Million)
3.9.3 Asia Pacific
3.9.3.1 Asia Pacific Glioblastoma Treatment Market Revenue, 2012 – 2022 (USD Million)
3.9.4 Rest of the World (RoW)
3.9.4.1 Rest of the World Glioblastoma Treatment Market Revenue, 2012 – 2022 (USD Million)
3.10 Competitive Landscape
3.10.1 Global Glioblastoma Treatment Market: Market Share, by Key Players 2013 (%)

Chapter 4 Global Pipeline Review of Glioblastoma Treatment
4.1 Overview
4.2 Pipeline Analysis : Types of Therapies
4.2.1 Targeted Therapy
4.2.1.1 TRC-105
4.2.2 Gene Therapy
4.2.2.1 VB-111
4.2.2.2 TOCA 511
4.2.3 Immunotherapy
4.2.3.1 DCVax-Brain
4.2.3.2 Rindopepimut (CDX-110)
4.2.3.3 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut
4.2.3.4 ICT-107
4.2.3.5 Trivax (AV00113)
4.3 Phase I and II Drug Entities

Chapter 5 Recommendations
5.1 Market Strategy for Success
5.1.1 Focus on the development of immunotherapy and biological therapy treatments
5.1.2 Development of novel drug delivery system (NDDS)
5.1.3 Expected intense competition in the near future

Chapter 6 Company Profiles
6.1 AbbVie, Inc.
6.1.1 Company Overview
6.1.2 Financial Overview
6.1.3 Product Portfolio
6.1.4 Business Strategies
6.1.4.1 Acquisitions and partnership for market penetration
6.1.5 Recent Developments
6.2 Activartis GmbH
6.2.1 Company Overview
6.2.2 Financial Overview
Being a privately owned company, the financial results of Activartis Biotech GmbH is not available in the public domain.
6.2.3 Product Portfolio
6.2.4 Business Strategies
6.2.4.1 Strong focus on research and development
6.2.5 Recent Developments
6.3 Agenus Inc.
6.3.1 Company Overview
6.3.2 Financial Overview
6.3.3 Product Portfolio
6.3.4 Business Strategies
6.3.4.1 Acquisition & Merger
6.3.5 Recent Developments
6.4 Arog Pharmaceuticals, Inc.
6.4.1 Company Overview
6.4.2 Financial Overview
6.4.3 Product Portfolio
6.4.4 Business Strategies
6.4.4.1 Research and development
6.4.5 Acquisition of worldwide rights
6.4.6 Recent Developments
6.5 Bristol-Myers Squibb Company
6.5.1 Company Overview
6.5.2 Financial Overview
6.5.3 Product Portfolio
6.5.4 Business Strategies
6.5.4.1 Acquisitions for company’s growth
6.5.5 Recent Developments
6.6 Cavion LLC
6.6.1 Company Overview
6.6.2 Financial Overview
6.6.3 Product Portfolio
6.6.4 Business Strategies
6.6.4.1 New Drug Development
6.7 Celldex Therapeutics Inc.
6.7.1 Company Overview
6.7.2 Financial Overview
6.7.3 Product Portfolio
6.7.4 Business Strategies
6.7.4.1 Strong Pipeline portfolio
6.7.5 Recent Developments
6.8 CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
6.8.1 Company Overview
6.8.2 Financial Overview
6.8.3 Product Portfolio
6.8.4 Business Strategies
6.8.4.1 Strong Pipeline portfolio
6.8.5 Recent Developments
6.9 Cortice Biosciences Inc.
6.9.1 Company Overview
6.9.2 Financial Overview
6.9.3 Product Portfolio
6.9.4 Business Strategies
6.9.4.1 Acquisition of Exclusive Commercial Rights
6.9.5 Recent Developments
6.10 Eisai Co., Ltd.
6.10.1 Company Overview
6.10.2 Financial Overview
6.10.3 Product Portfolio
6.10.4 Business Strategies
6.10.4.1 Joint Research Agreement
6.10.4.2 Introduction of new lifestyle information website for breast cancer patients
6.10.5 Recent Developments
6.11 Exelixis Inc.
6.11.1 Company Overview
6.11.2 Financial Overview
6.11.3 Product Portfolio
6.11.4 Business Strategies
6.11.4.1 Strong Pipeline portfolio
6.11.4.2 Partnered compounds
6.11.5 Recent Developments
6.12 F. Hoffmann-La Roche Ltd.
6.12.1 Company Overview
6.12.2 Financial Overview
6.12.3 Product Portfolio
6.12.4 Business Strategies
6.12.4.1 Investment in research and development (R&D)
6.12.4.2 Strengthening core business
6.12.4.3 Mergers and Acquisitions
6.12.5 Recent Developments
6.13 Peregrine Pharmaceuticals, Inc.
6.13.1 Company Overview
6.13.2 Financial Overview
6.13.3 Product Portfolio
6.13.4 Business Strategies
6.13.4.1 Licensing agreements and collaborations
6.13.4.2 Research and development approach
6.13.5 Recent Developments
6.14 OncoSynergy
6.14.1 Company Overview
6.14.2 Financial Overview
6.14.3 Product Portfolio
6.14.4 Business Strategies
6.14.5 Recent Developments
6.15 Merrimack Pharmaceuticals, Inc.
6.15.1 Company Overview
6.15.2 Financial Overview
6.15.3 Product Portfolio
6.15.4 Business Strategies
6.15.4.1 Acquisition and collaboration agreement to gain market share
6.15.5 Recent Developments



List of Tables

TABLE 1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022) 15

TABLE 2 Signatures and Clinical features of GBM subtypes 21

TABLE 3 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma 32

TABLE 4 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million) 40

TABLE 5 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut 58

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 多形膠芽細胞腫治療(GBM)の世界市場(Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆